Multiple Myeloma CAR-T Market Set for Rapid Growth Driven by BCMA-Targeted Therapies and Innovative Advances

The multiple myeloma CAR-T market is growing due to the strong clinical success of BCMS-targeted therapies and rising cases of relapsed or refractory patients, reports Towards Healthcare a sister firm of Precedence Research.

Ottawa, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The global multiple myeloma CAR-T market is experiencing rapid growth, with projected revenues expected to reach hundreds of millions between 2025 and 2034. This expansion is driven by rising investments, technological innovation, and increasing demand across healthcare sectors.

The market’s momentum is largely fueled by the success of BCMA-targeted therapies, such as Carvykti and Abecma, which have shown high response rates in treating relapsed or refractory multiple myeloma patients. Continued advancements in cell engineering, expanding clinical trial activity, and supportive regulatory frameworks are further accelerating adoption, positioning CAR-T therapies as a transformative approach in multiple myeloma treatment.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5812

Key Takeaways

North America dominated the multiple myeloma CAR-T market with a revenue share of >50% in 2024.
Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
By targeted antigen, the BCMA segment dominated the market with a revenue share of 85-90% in 2024.
By targeted antigen, the dual-targeted segment is expected to grow at the fastest CAGR in the market during the studied years.
By product type, the autologous CAR-T cells segment held the largest market share of 90-92% in 2024.
By product type, the allogenic CAR-T cells segment is expected to grow at the fastest CAGR in the market during the studied years.
By line of therapy, the third line and beyond segment led the market with the largest revenue share of 70-75% in 2024.
By line of therapy, the front-line segment is expected to grow at the fastest CAGR in the market during the studied years.
By end user, the hospitals (Academic & Specialized Cancer Centers) segment held the highest market share of 80-84% in 2024.
By end user, the specialty clinics segment is expected to grow at the fastest CAGR in the market during the studied years.
By distribution channel, the hospital pharmacies segment dominated the market with a market revenue of 75-80% in 2024.
By distribution channel, the specialty pharmacies segment is expected to grow at the fastest CAGR in the market during the studied years.
By technology/vector type, the lentiviral vector segment held the major market share of 65-70% in 2024.
By technology/vector type, the non-viral methods segment is expected to grow at the fastest CAGR in the market during the studied years.
By manufacturing type, the in-house manufacturing segment held the highest market share of 70-75% in 2024.
By manufacturing type, the contract manufacturing organizations segment is expected to grow at the fastest CAGR in the market during the studied years.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Market Overview & Potential

The Market refers to the market for chimeric antigen receptor T-cell (CAR-T) therapies developed and approved for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells in the bone marrow. These therapies involve genetically modifying a patient's T-cells to recognize and attack myeloma cells, primarily targeting surface antigens such as BCMA (B-cell maturation antigen).

The market includes products in clinical and commercial stages, manufacturing and supply chain services, and distribution models globally. The market is rapidly evolving, driven by the success of BCMA-targeted treatments like Abecma and Carvykti, which have demonstrated high response rates in relapsed or refractory patients. Recent FDA approvals have expanded their use to earlier lines of therapy, enhancing their clinical utility.

What Is The Growth Potential Responsible For The Growth Of The Multiple Myeloma CAR-T Market?

Major factors driving the Multiple Myeloma CAR-T market include the increasing rate of hematologic cancers, especially multiple myeloma, approval of new CAR-T therapies by regulatory agencies, substantial investments in R&D for innovative drugs and technologies like CRISPR, and a rising need for personalized medicine. The global rise in cancers, particularly hematologic malignancies such as multiple myeloma, boosts demand for advanced treatments like CAR-T cell therapy. Moreover, growing healthcare infrastructure, a focus on patient-centered care, and supportive regulatory policies in key markets further propel the market's expansion.

What Are the Growing Trends Associated with the Multiple Myeloma CAR-T Market?

Technological Innovations:

Development of new CAR-T cell technologies, including in vivo CAR T-cell programming, is improving treatment approaches.

Focus on Efficacy and Survival:

Ongoing research explores combining CAR-T therapy with other agents, such as bispecific antibodies and immunomodulatory drugs, to further enhance response rates and long-term survival.

Manufacturing Advancements:

Efforts are underway to simplify and improve the complex manufacturing processes associated with CAR-T therapy.

Addressing Challenges:

The market is working to overcome hurdles such as high treatment costs and potential side effects, including neurotoxicity and cytokine release syndrome.

Expansion in Emerging Economies:

There is a significant opportunity for market growth in emerging economies, provided that infrastructure and skilled professionals are developed.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

What Is the Growing Challenge in the Multiple Myeloma CAR-T Market?

The key challenges associated with the multiple myeloma (MM) CAR-T cell therapy market include the high cost of manufacturing, as it requires patient-specific cell collection and customization, patient-specific limitations, as the T-cells weaken due to the disease or due to previous therapies, also making the therapy less effective, which is a major challenge associated with the market growth. The other two major challenges with the therapy are the toxicity risk and treatment resistance due to incomplete responses, which limit the growth of the market.

Regional Analysis

How Did North America Dominate the Multiple Myeloma CAR-T Market in 2024?

North America dominated the multiple myeloma CAR-T market with a revenue share of >50% in 2024. The growth of the market is driven by the presence of global leaders like global pharmaceutical and biotechnology companies, which invest in the development and commercialization of CAR T-cell therapies. The advancement ad high healthcare expenditure and infrastructure with advanced healthcare systems and investment in research and development also support the adoption of innovative therapies, which drive the growth and expansion of the market in the region.

What Made the Asia Pacific Significantly Grow in The Multiple Myeloma CAR-T Market In 2024?

Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period. The growth of the market in the region is driven by the growing incidence of cancer prevalence, which demands innovative and effective treatments in the healthcare driving the growth of the market in the region. The government support and investments, like providing substantial financial support and developing favourable policies for cutting-edge treatments like CAR T-cell therapies, also support the growth of the market in the region. The growth is also supported by the technological advancements in gene editing technologies, which make the production more precise and effective, boosting the growth and expansion of the market.

Download the single region market report @ https://www.towardshealthcare.com/price/5812

Segmental Insights

By Targeted Antigen,

The BCMA segment dominated the market with a revenue share of 85-90% in 2024. BCMA-targeted CAR-T therapies dominate the market as they show high remission rates in relapsed multiple myeloma. FDA-approved products like Abecma and Carvykti validate their efficacy. Research focuses on enhancing durability and reducing side effects through improved vector design and combination strategies with checkpoint inhibitors.

The dual-targeted segment is expected to grow at the fastest CAGR in the market during the studied years. Dual-targeted CAR-T therapies combine BCMA with additional antigens such as GPRC5D or CD19 to prevent relapse from antigen escape. These multi-antigen constructs offer enhanced tumor clearance and response sustainability. U.S. trials emphasize dual-target approaches for next-generation treatments with broader applicability and improved patient outcomes.

By Product Type,

The autologous CAR-T cells segment held the largest market share of 90-92% in 2024. Autologous CAR-T therapies, derived from patients’ own T-cells, dominate the U.S. market for their proven compatibility and reduced immune rejection. Challenges include high costs and long manufacturing times, driving innovation in automated, scalable production and cryopreservation technologies to enhance efficiency and availability.

The allogenic CAR-T cells segment is expected to grow at the fastest CAGR in the market during the studied years. Allogeneic, or “off-the-shelf,” CAR-T therapies promise faster production and reduced cost. Using healthy donor cells, these options address autologous limitations. U.S. biotech companies are advancing clinical trials leveraging gene-editing technologies to mitigate immune rejection and expand access to broader patient populations.

By Line Of Therapy,

The third line and beyond segment led the market with the largest revenue share of 70-75% in 2024. CAR-T therapies are mainly used for relapsed or refractory multiple myeloma after multiple prior treatments. They deliver high response rates and durable remissions in difficult-to-treat patients, establishing themselves as essential salvage options in advanced treatment lines.

The front-line segment is expected to grow at the fastest CAGR in the market during the studied years. Ongoing U.S. studies explore CAR-T therapy as an early-line intervention to improve long-term survival. Integrating CAR-T in first-line regimens could potentially reduce relapse rates and replace stem cell transplantation for eligible patients.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

By End User,

The hospitals (Academic & Specialized Cancer Centers) segment held the highest market share of 80-84% in 2024. Academic hospitals and cancer centers dominate CAR-T therapy administration in the U.S. They possess the infrastructure for apheresis, infusion, and post-therapy monitoring, ensuring patient safety and high procedural success rates through specialized medical teams.

The specialty clinics segment is expected to grow at the fastest CAGR in the market during the studied years. Specialty oncology clinics increasingly deliver CAR-T therapies through outpatient programs. They enhance accessibility, support post-treatment care, and expand beyond major hospital networks with manufacturer partnerships and trained staff for localized therapy delivery.

By Distribution Channel,

The hospital pharmacies segment dominated the market with a market revenue of 75-80% in 2024. Hospital pharmacies manage CAR-T logistics, including storage, dispensing, and infusion coordination. They maintain strict quality control, liaise with manufacturers, and oversee reimbursement for complex therapies.

The specialty pharmacies segment is expected to grow at the fastest CAGR in the market during the studied years. Specialty pharmacies handle patient onboarding, insurance processing, and supply chain management for CAR-T therapies. They bridge manufacturers, hospitals, and patients to ensure timely access and adherence to therapy protocols.

By Technology/Vector Type,

The lentiviral vector segment held the major market share of 65-70% in 2024. Lentiviral vectors are widely used for CAR-T manufacturing due to their stable gene integration and strong expression in T-cells. They dominate current FDA-approved CAR-T products and continue to be refined for greater safety and production scalability.

The non-viral methods segment is expected to grow at the fastest CAGR in the market during the studied years. Non-viral delivery methods like transposon systems and CRISPR electroporation are gaining traction in the U.S. for lower cost and manufacturing flexibility. These techniques reduce viral vector dependency while improving efficiency in CAR-T cell modification.

By Manufacturing Type,

The in-house manufacturing segment held the highest market share of 70-75% in 2024. In-house CAR-T manufacturing enables full control over production timelines and quality. Major U.S. hospitals and biopharma companies use integrated facilities to accelerate clinical delivery and ensure compliance with FDA standards.

The contract manufacturing organizations segment is expected to grow at the fastest CAGR in the market during the studied years. CMOs provide scalable, cost-efficient CAR-T production for emerging biotech firms. They offer specialized infrastructure, regulatory expertise, and rapid turnaround, supporting the commercial expansion of multiple myeloma CAR-T therapies.

Browse More Insights of Towards Healthcare:

The global autologous stem cell and non-stem cell therapies market was valued at US$ 5.15 billion in 2024, is projected to reach US$ 6.81 billion in 2025, and is expected to surge to approximately US$ 82.32 billion by 2034, growing at a CAGR of 32.26% between 2025 and 2034.

The in vivo CAR-T platform market is witnessing rapid global expansion, with revenue projections anticipated to reach hundreds of millions between 2025 and 2034. Similarly, the next-generation CAR-T therapy market is on an upward trajectory, poised for substantial revenue growth during the same period.

The full-coverage chemotherapy market continues to advance globally, with expectations of generating hundreds of millions in revenue over the forecast years. Meanwhile, the CAR-T cell therapy isolator market is projected to experience significant growth, potentially reaching hundreds of millions in revenue by 2034.

The global multiple myeloma market is estimated at US$ 27.75 billion in 2024, projected to grow to US$ 29.43 billion in 2025, and expected to reach approximately US$ 49.89 billion by 2034, reflecting a CAGR of 6.04% between 2025 and 2034.

The autologous cell therapy market is valued at US$ 9.6 billion in 2024, expected to increase to US$ 11.41 billion in 2025, and projected to reach US$ 54.21 billion by 2034, expanding at a CAGR of 18.9%.

The cell therapy media market is set to grow from US$ 1.34 billion in 2024 to US$ 1.49 billion in 2025, reaching around US$ 3.83 billion by 2034, representing a CAGR of 11.14%.

The stem cell therapy market is expected to grow from US$ 490 million in 2024 to US$ 613.7 million in 2025, with forecasts indicating an expansion to US$ 4,777.4 million by 2034, at a CAGR of 25.26%.

Lastly, the automated and closed cell therapy processing systems market is projected to increase from US$ 1.45 billion in 2024 to US$ 1.74 billion in 2025, and reach approximately US$ 8.86 billion by 2034, growing at a CAGR of 19.84%.

Recent Developments

In November 2024, Maharaja Yashwantrao Hospital at MGM Medical College introduced CAR T-cell therapy for blood cancer treatment, marking a major advancement in India’s cancer care landscape. This development represents a crucial step forward in offering advanced, targeted therapies for patients battling blood-related malignancies.
In September 2024, Moffitt Cancer Center entered into a strategic partnership with AstraZeneca aimed at advancing the development of CAR T-cell and T-cell receptor therapies. This collaboration is focused on accelerating research and innovation in next-generation immunotherapies for cancer treatment.

Multiple Myeloma CAR-T Market Key Players List

Bristol Myers Squibb 
Johnson & Johnson (Legend Biotech) 
Novartis AG 
Pfizer Inc. 
Gilead Sciences (Kite Pharma) 
Autolus Therapeutics
Poseida Therapeutics
Bluebird Bio 
Caribou Biosciences 
Gracell Biotechnologies
Allogene Therapeutics
Precision BioSciences
Celyad Oncology
Tessa Therapeutics
Sorrento Therapeutics
Umoja Biopharma
IASO Biotherapeutics 
JW Therapeutics 
Miltenyi Biotec 
Senti Biosciences

Download the Competitive Landscape market report @ https://www.towardshealthcare.com/price/5812

Segments Covered in The Report

By Target Antigen 

BCMA (B-Cell Maturation Antigen)
GPRC5D 
CD38 
CD138
SLAMF7 
Dual-targeted (e.g., BCMA + CD19)

By Product Type 

Autologous CAR-T Cells
Allogeneic CAR-T Cells

By Line of Therapy

Third Line and Beyond
Second Line
Front-Line

By End User 

Hospitals (Academic & Specialized Cancer Centers)
Specialty Clinics 
Contract Research Organizations (for trial settings)

By Distribution Channel

Hospital Pharmacies
Specialty Pharmacies
Direct-to-Patient (limited, emerging)

By Technology/Vector Type 

Lentiviral Vectors
Retroviral Vectors 
Non-viral Methods (e.g., CRISPR, Sleeping Beauty)

By Manufacturing Type 

In-house Manufacturing
Contract Manufacturing Organizations (CMO)

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5812

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.